Lateral Flow Diagnostics Market Poised to Reach $13.52 Billion by 2031

Demand for point-of-care diagnostics remains anchored by the persistent prevalence of infectious diseases and an aging global population requiring regular health monitoring. Beyond traditional qualitative tests, the industry is shifting toward quantitative, multiplex-detection tools capable of identifying cardiac markers and chronic conditions. This transition is supported by innovations in nanomaterial-based labels and signal-amplification technologies, which enhance the reliability of home-based and clinical testing.

North America currently commands the largest market share, holding 42.3% of the sector in 2025, bolstered by advanced healthcare infrastructure and significant capital investment. Corporate strategy reflects this growth: major players like Roche and bioMérieux are securing supply chain capacity and acquiring specialized startups to consolidate their hold on decentralized testing. Recent funding rounds, including multi-million dollar injections into firms like OraSure and Abingdon Health, underscore a broader move to scale manufacturing and integrate AI-powered result interpretation into everyday diagnostic workflows.